We are studying the role of prolyl oligopeptidase (PREP, formerly known as POP) on disease progression and neuronal toxicity in neurodegenerative disorders with protein aggregation. These disorders include several serious diseases such as Alzheimer’s and Parkinson’s diseases, and several more rare neurodegenerative conditions. Based on PREP inhibitors, we are developing novel and disease-modifying drug therapies to stop neuronal death in Alzheimer's and Parkinson's diseases.